Development
Rapid Dose Therapeutics Corp.
DOSE
CNSX
| 11/30/2023 | 08/31/2023 | 05/31/2023 | 02/28/2023 | 11/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 774.90K | 830.30K | 668.90K | 540.00K | 493.60K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 774.90K | 830.30K | 668.90K | 540.00K | 493.60K |
| Cost of Revenue | 413.30K | 394.80K | 326.50K | 259.60K | 300.30K |
| Gross Profit | 361.60K | 435.60K | 342.50K | 280.50K | 193.40K |
| SG&A Expenses | 1.95M | 1.86M | 2.08M | 2.44M | 3.62M |
| Depreciation & Amortization | 535.80K | 507.00K | 491.50K | 474.40K | 505.70K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.04M | 2.85M | 2.94M | 3.24M | 4.57M |
| Operating Income | -2.26M | -2.02M | -2.28M | -2.70M | -4.08M |
| Income Before Tax | -2.65M | -2.37M | -2.53M | -2.90M | -7.39M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.65 | -2.37 | -2.53 | -2.90 | -7.39 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.65M | -2.37M | -2.53M | -2.90M | -7.39M |
| EBIT | -2.26M | -2.02M | -2.28M | -2.70M | -4.08M |
| EBITDA | -2.04M | -1.82M | -2.09M | -2.54M | -3.97M |
| EPS Basic | -0.03 | -0.02 | -0.02 | -0.03 | -0.07 |
| Normalized Basic EPS | -0.02 | -0.01 | -0.02 | -0.02 | -0.02 |
| EPS Diluted | -0.03 | -0.02 | -0.02 | -0.03 | -0.07 |
| Normalized Diluted EPS | -0.02 | -0.01 | -0.02 | -0.02 | -0.02 |
| Average Basic Shares Outstanding | 414.31M | 413.78M | 413.60M | 413.30M | 416.05M |
| Average Diluted Shares Outstanding | 414.31M | 413.78M | 413.60M | 413.30M | 416.05M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |